My PCR
Create Account
Logo PCR

20 May 2025

LAA closure

Broadening OPTIONs for LAA closure: innovations and outcomes

Sponsored by Boston Scientific

Anchorperson: J. E. Nielsen-Kudsk
Spokesperson: C. Skurk
SHOW MORE

Summary

Explore the latest insights into LAA closure from EuroPCR 2025. This session highlights results from the OPTION trial—the largest RCT comparing LAAC (with Watchman FLX) to DOAC therapy in AF patients undergoing ablation. The findings? Comparable stroke prevention at 3 years, with a 56 % reduction in non-procedural bleeding. You'll also hear how LAAC with Watchman FLX offers flexibility in timing—whether performed during or after ablation—and discover the expanded capabilities of the Watchman FLX Pro, now suited for very large LAAs thanks to its new 40 mm size and thromboresistant coating.

Learning Objectives

  • To discuss the clinical data from the OPTION trial and its implications for practice
  • To understand how OPTION trial findings could influence clinical decision-making
  • To discover upcoming innovations in the WATCHMAN FLX product pipeline
Related Content
PCR Textbook chapter on Left atrial appendage occlusion: free access until 4 October The expanding practice of LAAC today in case examples Structural heart: demanding anatomies, difficult situations and unusual strategies
Recommended for you
Register at Regular fee GulfPCR-GIM 2025 – What's on the Programme? AICT-AsiaPCR: what's in store this year?